PMID- 37051072
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230415
IS  - 2040-6223 (Print)
IS  - 2040-6231 (Electronic)
IS  - 2040-6223 (Linking)
VI  - 14
DP  - 2023
TI  - Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a 
      meta-analysis of randomized clinical trials.
PG  - 20406223231163110
LID - 10.1177/20406223231163110 [doi]
LID - 20406223231163110
AB  - BACKGROUND: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits 
      both interleukin (IL)-17A and IL-17F, and is a promising drug for patients with 
      moderate-to-severe plaque psoriasis. OBJECTIVES: This study aimed to assess the 
      efficacy and safety of bimekizumab in treating patients with psoriasis and to 
      determine the optimal maintenance dosing schedules of bimekizumab. METHODS AND 
      DESIGN: Eligible trials were identified from PubMed, Cochrane Controlled Register 
      of Trials, Embase, ClinicalTrials.gov, and Chinese medical databases. Only 
      double-blind, randomized, active comparator, or placebo-controlled trials of 
      bimekizumab treatment on patients with psoriasis were included in this study. 
      RESULTS: Five studies were identified, which included 2473 patients with 
      moderate-to-severe plaque psoriasis. The results indicated that bimekizumab had 
      better efficacy than placebo or active comparator for Psoriasis Area and Severity 
      Index (PASI) 90 [risk ratio (RR) = 29.29, 1.52; 95% confidence interval 
      (CI) = 10.30-83.30, 1.06-2.19], PASI 100 (RR = 59.87, 2.06; 95% 
      CI = 15.06-237.99, 1.12-3.79), and Investigator's Global Assessment scores of 0 
      or 1 (IGA 0/1) (RR = 21.55, 1.36; 95% CI = 9.25-50.19, 1.02-1.81). Faster onset 
      of clinically meaningful responses was observed with bimekizumab compared with 
      both active comparators (RR = 2.59; 95% CI = 1.32-5.10) and placebo (RR = 40.46; 
      95% CI = 13.19-124.13), with PASI 75 response observed at week 4 after one dose. 
      Subgroup analysis showed no significant difference in the reduction of PASI 
      scores between 320 mg q4w dosage and q8w dosage (RR = 1.00; 95% CI = 0.96-1.03). 
      Rates of patients with adverse events (AEs) were comparable in the bimekizumab 
      and active comparator groups (RR = 1.13; 95% CI = 1.01-1.26), and oral 
      candidiasis was one of the most common treatment-emergent AEs. CONCLUSION: The 
      results of this meta-analysis suggest that bimekizumab is more efficacious and 
      has a rapid onset of action than active comparators and placebo in the treatment 
      of moderate-to-severe plaque psoriasis. After 16 weeks of initial maintenance 
      treatment, both bimekizumab maintenance dosing schedules (320 mg every 4 and 
      8 weeks) had similar efficacy.
CI  - (c) The Author(s), 2023.
FAU - Wang, Yuqian
AU  - Wang Y
AUID- ORCID: 0000-0003-3711-6528
AD  - Department of Dermatology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, People's Republic of China.
FAU - Li, Sheng
AU  - Li S
AD  - Department of Dermatology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, People's Republic of China.
FAU - Bai, Juan
AU  - Bai J
AD  - Department of Dermatology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, People's Republic of China.
FAU - Cai, Xiaoxuan
AU  - Cai X
AD  - Department of Dermatology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, People's Republic of China.
FAU - Tang, Shunli
AU  - Tang S
AD  - Department of Dermatology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, People's Republic of China.
FAU - Lin, Peiyi
AU  - Lin P
AD  - Department of Dermatology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, People's Republic of China.
FAU - Sun, Qingmiao
AU  - Sun Q
AD  - Department of Dermatology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, People's Republic of China.
FAU - Qiao, Jianjun
AU  - Qiao J
AD  - Department of Dermatology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, No. 79 Qingchun Road, Hangzhou 310000, People's Republic of 
      China.
FAU - Fang, Hong
AU  - Fang H
AD  - Department of Dermatology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, No. 79 Qingchun Road, Hangzhou 310000, People's Republic of 
      China.
LA  - eng
PT  - Journal Article
DEP - 20230404
PL  - United States
TA  - Ther Adv Chronic Dis
JT  - Therapeutic advances in chronic disease
JID - 101532140
PMC - PMC10084576
OTO - NOTNLM
OT  - bimekizumab
OT  - meta-analysis
OT  - plaque psoriasis
OT  - randomized controlled trial
COIS- The authors declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2023/04/14 06:00
MHDA- 2023/04/14 06:01
PMCR- 2023/04/04
CRDT- 2023/04/13 01:56
PHST- 2022/08/17 00:00 [received]
PHST- 2023/02/24 00:00 [accepted]
PHST- 2023/04/14 06:01 [medline]
PHST- 2023/04/13 01:56 [entrez]
PHST- 2023/04/14 06:00 [pubmed]
PHST- 2023/04/04 00:00 [pmc-release]
AID - 10.1177_20406223231163110 [pii]
AID - 10.1177/20406223231163110 [doi]
PST - epublish
SO  - Ther Adv Chronic Dis. 2023 Apr 4;14:20406223231163110. doi: 
      10.1177/20406223231163110. eCollection 2023.